Self-Amplifying RNA VLP Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid global transmission of pathogens due to globalization poses a significant challenge in managing emerging infectious diseases like SARS-CoV-2, necessitating effective preventive vaccines that can induce robust immune responses with stability and efficacy.
Innovation Solution
Development of self-amplifying mRNA (sa-RNA) virus-like particles (VLPs) that incorporate a recombinant alphavirus replicon encoding immunogenic antigens, a retroviral gag protein, and a fusogenic envelope protein, specifically designed to be stable for extended periods and capable of inducing T cell responses against SARS-CoV-2 upon administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional viral vectors or mRNA vaccines are used, then immune response induction is achieved, but storage stability and shelf life are limited
Solution Approach 1:
The patent modifies the physical and chemical parameters of the vaccine formulation by incorporating lipids, sugars, and salts into the VLP structure, changing the storage temperature parameters from refrigeration to ambient temperatures, and extending the shelf life from weeks to months while maintaining immunogenicity
Solution Approach 2:
The invention creates a composite structure by combining self-amplifying RNA with virus-like particles that contain multiple functional components (structural proteins, non-structural proteins, packaging signals), and further composite the VLPs with stabilizing agents and formulation excipients to achieve both stability and functionality
2Reliability
If complex viral vectors are used to deliver immunogenic antigens, then immune response is induced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the vaccine into distinct functional modules: the self-amplifying RNA component containing immunogenic antigen sequences, the VLP structural components, and the formulation excipients. This segmentation allows independent optimization and simplifies manufacturing by enabling separate production and assembly steps
Solution Approach 2:
The self-amplifying RNA component performs its own replication and amplification within host cells without requiring external viral vectors or complex delivery systems, thereby simplifying the manufacturing process while maintaining effective immune response induction
Data Source
AI summary
The present disclosure provides compositions comprising an sa-RNA VLP vaccine (e.g. the VLP vaccine) that is capable of delivering a self-amplifying RNA to a target cell in a patient, and subsequently elicit an immune response in the patient, which immune response is sufficient to prevent or significantly decrease the duration of an infection by an infectious agent, such as SARS-CoV-2.